NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021

Featured Updates to the NCCN Guidelines

View More View Less
  • 1 University of Wisconsin Carbone Cancer Center;
  • | 2 UC San Diego Moores Cancer Center;
  • | 3 Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;
  • | 4 University of Colorado Cancer Center;
  • | 5 UCSF Helen Diller Family Comprehensive Cancer Center;
  • | 6 Massachusetts General Hospital Cancer Center;
  • | 7 Roswell Park Comprehensive Cancer Center;
  • | 8 Lynch Syndrome International;
  • | 9 Moffitt Cancer Center;
  • | 10 O'Neal Comprehensive Cancer Center at UAB;
  • | 11 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;
  • | 12 Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;
  • | 13 Fox Chase Cancer Center;
  • | 14 The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;
  • | 15 Stanford Cancer Institute;
  • | 16 City of Hope National Medical Center;
  • | 17 Huntsman Cancer Institute at the University of Utah;
  • | 18 Abramson Cancer Center at the University of Pennsylvania;
  • | 19 University of Michigan Rogel Cancer Center;
  • | 20 Yale Cancer Center/Smilow Cancer Hospital;
  • | 21 The University of Texas MD Anderson Cancer Center;
  • | 22 Memorial Sloan Kettering Cancer Center;
  • | 23 UT Southwestern Simmons Comprehensive Cancer Center;
  • | 24 Mayo Clinic Cancer Center;
  • | 25 St. Jude Children's Research Hospital/The University of Tennessee Health Science Center;
  • | 26 Fred & Pamela Buffett Cancer Center;
  • | 27 Robert H. Lurie Comprehensive Cancer Center of Northwestern University;
  • | 28 Vanderbilt-Ingram Cancer Center;
  • | 29 Duke Cancer Institute;
  • | 30 Dana-Farber/Brigham and Women's Cancer Center;
  • | 31 UCLA Jonsson Comprehensive Cancer Center; and
  • | 32 National Comprehensive Cancer Network.

Identifying individuals with hereditary syndromes allows for timely cancer surveillance, opportunities for risk reduction, and syndrome-specific management. Establishing criteria for hereditary cancer risk assessment allows for the identification of individuals who are carriers of pathogenic genetic variants. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal provides recommendations for the assessment and management of patients at risk for or diagnosed with high-risk colorectal cancer syndromes. The NCCN Genetic/Familial High-Risk Assessment: Colorectal panel meets annually to evaluate and update their recommendations based on their clinical expertise and new scientific data. These NCCN Guidelines Insights focus on familial adenomatous polyposis (FAP)/attenuated familial adenomatous polyposis (AFAP) syndrome and considerations for management of duodenal neoplasia.

  • 1.

    Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin 2021;71:733.

  • 2.

    Cheng L, Eng C, Nieman LZ, et al. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol 2011;34:573580.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Bailey CE, Hu CY, You YN, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg 2015;150:1722.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol 2006;101:385398.

  • 5.

    Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis 2009;4:22.

  • 6.

    Ballhausen WG. Genetic testing for familial adenomatous polyposis. Ann N Y Acad Sci 2000;910:3647.

  • 7.

    Mihalatos M, Apessos A, Papadopoulou E, et al. Genetic alterations of the APC gene in familial adenomatous polyposis patients of the Hellenic group for the study of colorectal cancer. Anticancer Res 2003;23:21912193.

    • Search Google Scholar
    • Export Citation
  • 8.

    Aretz S, Uhlhaas S, Caspari R, et al. Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis. Eur J Hum Genet 2004;12:5258.

  • 9.

    Bisgaard ML, Fenger K, Bülow S, et al. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 1994;3:121125.

  • 10.

    Jansen AML, Goel A. Mosaicism in patients with colorectal cancer or polyposis syndromes: a systematic review. Clin Gastroenterol Hepatol 2020;18:19491960.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Bennouna J, Borg C, Delord JP, et al. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Clin Colorectal Cancer 2012;11:3844.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Bülow C, Bülow S. Is screening for thyroid carcinoma indicated in familial adenomatous polyposis? The Leeds Castle Polyposis Group. Int J Colorectal Dis 1997;12:240242.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Casellas-Cabrera N, Díaz-Algorri Y, Carlo-Chévere VJ, et al. Risk of thyroid cancer among Caribbean Hispanic patients with familial adenomatous polyposis. Fam Cancer 2016;15:267274.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Chenbhanich J, Atsawarungruangkit A, Korpaisarn S, et al. Prevalence of thyroid diseases in familial adenomatous polyposis: a systematic review and meta-analysis. Fam Cancer 2019;18:5362.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Feng X, Milas M, O’Malley M, et al. Characteristics of benign and malignant thyroid disease in familial adenomatous polyposis patients and recommendations for disease surveillance. Thyroid 2015;25:325332.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Giardiello FM, Offerhaus GJ, Lee DH, et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993;34:13941396.

  • 17.

    Herraiz M, Barbesino G, Faquin W, et al. Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol 2007;5:367373.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Jarrar AM, Milas M, Mitchell J, et al. Screening for thyroid cancer in patients with familial adenomatous polyposis. Ann Surg 2011;253:515521.

  • 19.

    Mankaney G, Leone P, Cruise M, et al. Gastric cancer in FAP: a concerning rise in incidence. Fam Cancer 2017;16:371376.

  • 20.

    Sada H, Hinoi T, Ueno H, et al. Prevalence of and risk factors for thyroid carcinoma in patients with familial adenomatous polyposis: results of a multicenter study in Japan and a systematic review. Surg Today 2019;49:7281.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Steinhagen E, Hui VW, Levy RA, et al. Results of a prospective thyroid ultrasound screening program in adenomatous polyposis patients. Am J Surg 2014;208:764769.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Truta B, Allen BA, Conrad PG, et al. Genotype and phenotype of patients with both familial adenomatous polyposis and thyroid carcinoma. Fam Cancer 2003;2:9599.

  • 23.

    Yamaguchi T, Ishida H, Ueno H, et al. Upper gastrointestinal tumours in Japanese familial adenomatous polyposis patients. Jpn J Clin Oncol 2016;46:310315.

  • 24.

    Björk J, Akerbrant H, Iselius L, et al. Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations. Gastroenterology 2001;121:11271135.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Bülow S, Björk J, Christensen IJ, et al. Duodenal adenomatosis in familial adenomatous polyposis. Gut 2004;53:381386.

  • 26.

    Burke CA, Beck GJ, Church JM, et al. The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program. Gastrointest Endosc 1999;49:358364.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27.

    Groves CJ, Saunders BP, Spigelman AD, et al. Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut 2002;50:636641.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Heiskanen I, Kellokumpu I, Järvinen H. Management of duodenal adenomas in 98 patients with familial adenomatous polyposis. Endoscopy 1999;31:412416.

  • 29.

    Jagelman DG, DeCosse JJ, Bussey HJ. Upper gastrointestinal cancer in familial adenomatous polyposis. Lancet 1988;1:11491151.

  • 30.

    Kadmon M, Tandara A, Herfarth C. Duodenal adenomatosis in familial adenomatous polyposis coli. A review of the literature and results from the Heidelberg Polyposis Register. Int J Colorectal Dis 2001;16:6375.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Nugent KP, Spigelman AD, Williams CB, et al. Surveillance of duodenal polyps in familial adenomatous polyposis: progress report. J R Soc Med 1994;87:704706.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Saurin JC, Gutknecht C, Napoleon B, et al. Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol 2004;22:493498.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Levy RA, Hui VW, Sood R, et al. Cribriform-morular variant of papillary thyroid carcinoma: an indication to screen for occult FAP. Fam Cancer 2014;13:547551.

  • 34.

    Nieuwenhuis MH, Vasen HF. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol 2007;61:153161.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Caspari R, Olschwang S, Friedl W, et al. Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 1995;4:337340.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Aretz S, Koch A, Uhlhaas S, et al. Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations? Pediatr Blood Cancer 2006;47:811818.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Nusliha A, Dalpatadu U, Amarasinghe B, et al. Congenital hypertrophy of retinal pigment epithelium (CHRPE) in patients with familial adenomatous polyposis (FAP); a polyposis registry experience. BMC Res Notes 2014;7:734.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Sturt NJ, Gallagher MC, Bassett P, et al. Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation. Gut 2004;53:18321836.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Kennedy RD, Potter DD, Moir CR, et al. The natural history of familial adenomatous polyposis syndrome: a 24 year review of a single center experience in screening, diagnosis, and outcomes. J Pediatr Surg 2014;49:8286.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Knudsen AL, Bisgaard ML, Bülow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2003;2:4355.

  • 41.

    Gupta S, Lieberman D, Anderson JC, et al. Recommendations for follow-up after colonoscopy and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2020;158:11311153.e5.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Hegde MR, Roa BB. Detecting mutations in the APC gene in familial adenomatous polyposis (FAP). Curr Protoc Hum Genet 2006;Chapter 10:Unit 10.18.

  • 43.

    Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006;24:46424660.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Spigelman AD, Williams CB, Talbot IC, et al. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 1989;2:783785.

  • 45.

    Bülow S, Christensen IJ, Højen H, et al. Duodenal surveillance improves the prognosis after duodenal cancer in familial adenomatous polyposis. Colorectal Dis 2012;14:947952.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Kallenberg FGJ, Bastiaansen BAJ, Dekker E. Cap-assisted forward-viewing endoscopy to visualize the ampulla of Vater and the duodenum in patients with familial adenomatous polyposis. Endoscopy 2017;49:181185.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Samadder NJ, Neklason DW, Boucher KM, et al. Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial. JAMA 2016;315:12661275.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006;63:570580.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Abraham SC, Nobukawa B, Giardiello FM, et al. Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol 2000;157:747754.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Bianchi LK, Burke CA, Bennett AE, et al. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008;6:180185.

  • 51.

    Martin I, Roos VH, Anele C, et al. Gastric adenomas and their management in familial adenomatous polyposis. Endoscopy 2020;53:795801.

  • 52.

    Kunnathu ND, Mankaney GN, Leone PJ, et al. Worrisome endoscopic feature in the stomach of patients with familial adenomatous polyposis: the proximal white mucosal patch. Gastrointest Endosc 2018;88:569570.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Leone PJ, Mankaney G, Sarvapelli S, et al. Endoscopic and histologic features associated with gastric cancer in familial adenomatous polyposis. Gastrointest Endosc 2019;89:961968.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Walton SJ, Kallenberg FG, Clark SK, et al. Frequency and features of duodenal adenomas in patients with MUTYH-associated polyposis. Clin Gastroenterol Hepatol 2016;14:986992.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015;110:223262.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Groen EJ, Roos A, Muntinghe FL, et al. Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol 2008;15:24392450.

  • 57.

    Monachese M, Mankaney G, Lopez R, et al. Outcome of thyroid ultrasound screening in FAP patients with a normal baseline exam. Fam Cancer 2019;18:7582.

  • 58.

    Friedl W, Caspari R, Sengteller M, et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut 2001;48:515521.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Church J, Lynch C, Neary P, et al. A desmoid tumor-staging system separates patients with intra-abdominal, familial adenomatous polyposis-associated desmoid disease by behavior and prognosis. Dis Colon Rectum 2008;51:897901.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Church J, Berk T, Boman BM, et al. Staging intra-abdominal desmoid tumors in familial adenomatous polyposis: a search for a uniform approach to a troubling disease. Dis Colon Rectum 2005;48:15281534.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Quintini C, Ward G, Shatnawei A, et al. Mortality of intra-abdominal desmoid tumors in patients with familial adenomatous polyposis: a single center review of 154 patients. Ann Surg 2012;255:511516.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Attard TM, Giglio P, Koppula S, et al. Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis. Cancer 2007;109:761766.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2217 2217 205
PDF Downloads 2061 2061 204
EPUB Downloads 0 0 0